Dry eye partnership expands treatment options

Positive Impact has become the UK partner of Lumenis BE, a medical device company for eye care and aesthetic applications, and will provide professional support, education and clinical training for OptiLight.

OptiLight is approved by the Food and Drug Administration in the US for the management of dry eye disease due to meibomian gland dysfunction with its patented optimal pulse technology. It provides targeted, uniform and controlled treatment that breaks the cycle of inflammation, the company said.

Nick Atkins, managing director at Positive Impact, said: ‘OptiLight fits perfectly with our business ethos of only working with best-in-class products that offer differentiation and generate sales for the independent practice. I have long felt that the future of successful dry eye management, both clinically and commercially, lies with professional in-practice treatment options.’